Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
Agios Pharmaceuticals shares rose 13.8% this week after the FDA granted priority review for Agios’ oral pyruvate kinase activator mitapivat in sickle cell disease. Mitapivat is already approved for PK deficiency and thalassemia. The FDA decision is due by Nov. 1, with confirmatory REIGNITE 3 required.
How this was made
The 30-second read
Why it matters
The FDA priority review designation is a concrete regulatory step that can accelerate the timeline and improve perceived probability of an accelerated approval decision, but full approval still depends on REIGNITE 3 outcomes.
Market read
A regulatory catalyst (priority review) explains a sharp weekly move and frames the next decision milestone for mitapivat in SCD.
What to watch
The article highlights mixed Phase 3 RISE UP results on the primary SCPC endpoint, so investors may reprice risk if FDA focuses on that endpoint or additional data requirements.
Background
Mitapivat is already approved for PK deficiency and thalassemia; Agios is seeking approval for SCD as the first oral PK activator.
Ticker impact
Agios shares jumped as the FDA announced it will grant priority review for mitapivat in sickle cell disease.
Near-term upside bias into the FDA decision window, with volatility around any FDA questions or confirmatory-trial expectations.
The article cites a specific FDA action (priority review) tied to Agios' SCD indication and notes an accelerated approval decision deadline (Nov. 1).
Market effects
Reinforces regulatory momentum for oral therapies in sickle cell disease and may heighten competitive scrutiny of PK activators.
Limited, primarily US biotech regulatory-driven sentiment.
Moderate, as FDA priority review can influence global expectations for SCD treatment timelines.
Counterpoint
Priority review does not guarantee approval; the confirmatory REIGNITE 3 trial still needs to support full approval.
Key entities
- companyAgios Pharmaceuticals
Sponsor of mitapivat and the subject of the FDA priority review announcement for SCD.
- drugMitapivat
Oral pyruvate kinase activator being evaluated for sickle cell disease.
- regulatorFDA
Announced priority review for mitapivat in sickle cell disease.
- clinical_trialRISE UP trial
Phase 3 trial in SCD with mixed results, including meeting hemoglobin endpoints but not statistical significance on annualized SCPC reduction.
- clinical_trialREIGNITE 3 trial
Confirmatory trial required for full approval after any accelerated approval.
